메뉴 건너뛰기
Translational Lung Cancer Research
Volumn 3, Issue 6, 2014, Pages 397-399
Angiogenesis and lung cancer: Ramucirumab prolongs survival in 2nd-line metastatic NSCLC
Author keywords

Angiogenesis; Docetaxel; Lung cancer; Ramucirumab; VEGF
Indexed keywords

EID: 84959876924     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.3978/j.issn.2218-6751.2014.09.05     Document Type: Editorial
Times cited : (12)
References (6)
  • 1
    • 84919389705 scopus 로고    scopus 로고
    • REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy
    • Perol M, Ciuleanu TE, Arrieta O, et al. REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy. J Clin Oncol 2014;32:abstr LBA8006.
    • (2014) J Clin Oncol , vol.32
    • Perol, M.1    Ciuleanu, T.E.2    Arrieta, O.3
  • 2
    • 84892852372 scopus 로고    scopus 로고
    • Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebocontrolled, phase 3 trial
    • Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebocontrolled, phase 3 trial. Lancet 2014;383:31-9.
    • (2014) Lancet , vol.383 , pp. 31-39
    • Fuchs, C.S.1    Tomasek, J.2    Yong, C.J.3
  • 3
    • 84906903314 scopus 로고    scopus 로고
    • Ramucirumab plus docetaxel versus placebo plus docetaxel for secondline treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
    • Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for secondline treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014;384:665-73.
    • (2014) Lancet , vol.384 , pp. 665-673
    • Garon, E.B.1    Ciuleanu, T.E.2    Arrieta, O.3
  • 4
    • 33845490014 scopus 로고    scopus 로고
    • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    • Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
    • (2006) N Engl J Med , vol.355 , pp. 2542-2550
    • Sandler, A.1    Gray, R.2    Perry, M.C.3
  • 5
    • 84892967581 scopus 로고    scopus 로고
    • Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUMELung 1): a phase 3, double-blind, randomised controlled trial
    • Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUMELung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014;15:143-55.
    • (2014) Lancet Oncol , vol.15 , pp. 143-155
    • Reck, M.1    Kaiser, R.2    Mellemgaard, A.3
  • 6
    • 84875937242 scopus 로고    scopus 로고
    • Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies
    • Li T, Kung HJ, Mack PC, et al. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 2013;31:1039-49.
    • (2013) J Clin Oncol , vol.31 , pp. 1039-1049
    • Li, T.1    Kung, H.J.2    Mack, P.C.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.